Xenon Pharmaceuticals Inc XENE

$40.48 -0.51 (-1.26%)

Valuation

Market cap
3,962,823,000
Revenue TTM
$7,500,000
Net income TTM
$-345,910,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-4,612.13%
Debt to equity
0.00

Trading

Volume
607,600
Avg volume
1,899,622
Day's range
$39.84 – $41.20
Shares out
96,666,000
Stochastic %K
66%
Beta
0.11
Analysts
Strong Buy
Price target
$71.11

Price

Company profile

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary genera...

Show more

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 484 3300
Website
https://www.xenon-pharma.com
Address
200-3650 Gilmore Way, Burnaby, Canada

Latest news

Stocktwits

Merlintrader Nov 11, 6:51 AM
$XENE Xenon (XENE): Q3 net loss $110.4M, cash runway into 2029 Free weekly catalyst newsletter: https://merlintrader.beehiiv.com/p/week-ahead-10-catalysts-we-re-watching-november-9-13 Not investment advice.
0 replies
Estimize Nov 10, 2:36 PM
$XENE reported -1.11 EPS and 0.00 revenue for Q3. http://www.estimize.com/intro/xene?chart=historical&metric_name=eps&utm_content=XENE&utm_
0 replies
shoc24 Nov 10, 6:24 AM
$XENE reported earnings after the close today. GAAP EPS beat estimates: -$1.11 vs. -$1.13 expected, according to Stock Meadow.
0 replies
EarningsInsider Nov 9, 10:54 PM
https://www.marketbeat.com/earnings/reports/2026-11-9-xenon-pharmaceuticals-inc-stock/ $XENE Xenon Pharmaceuticals Earnings Transcript
0 replies
StocktwitsEarnings Nov 9, 10:06 PM
$XENE Q3 '26 Earnings Results & Recap Reported GAAP EPS of -$1.11 up 3.48% YoY
0 replies
d_risk Nov 9, 9:52 PM
$XENE - Xenon Pharmaceuticals Inc. - 10-Q - Updated Risk Factors Xenon says it paused new enrollment in its MDD and BPD studies after reviewing certain neuropsychiatric adverse events. #riskfactors #secfilings 🟢 Added 🟠 Removed https://d-risk.ai/XENE?filing=P-oas8NyD4reLIaUoR30s
0 replies
Merlintrader Nov 9, 5:01 PM
$XENE Xenon to present at upcoming investor conferences (Nov 3) • Xenon Pharmaceuticals will present at four investor conferences in the fourth quarter of 2026, each as a fireside chat. • Upcoming: Financial results — Nov 9, 2026 • Dates include Guggenheim on November 10, Stifel on November 11, Jefferies London on November 18, and Evercore on December 1, 2026. Full hub (catalysts, filings & latest news): https://www.merlintrader.com/xenon-pharmaceuticals-stock-hub?utm_source=stocktwits&utm_medium=social&utm_campaign=st-hub-giro&utm_content=xene Free weekly catalyst newsletter — no free trials, no logins, FREE is FREE: https://merlintrader.beehiiv.com/subscribe?utm_source=stocktwits&utm_medium=social&utm_campaign=st-hub-giro&utm_content=xene Not investment advice.
0 replies
usedgum Nov 9, 1:04 PM
$XENE what does the day holds. She likes it. Let’s see if she was right about that dip a while back.
0 replies